Alexion Pharmaceuticals, Inc.
New England Journal of Medicine Publishes Case Reports on the Investigational Use of Soliris® eculizumab in Patients with Atypical Hemolytic Uremic Syndrome aHUS
Published in Medical Device Business Week, February 11th, 2009
Two separate case reports published in the New England Journal of Medicine (NEJM) examine the investigational use of Soliris ® (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), in patients with a rare and severe inflammatory disease called atypical Hemolytic Uremic Syndrome (aHUS). In both cases, physicians observed a significant reduction in the destruction of red blood cells, reduced platelet consumption and improved kidney function following Soliris therapy.
Separately, Alexion announced that it is currently initiating clinical trials of eculizumab in patients with aHUS. Soliris is approved in the United States,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Business Week
More Articles from Medical Device Business Week
- Analogic Corporation
Analogic Corporation Announces Restructuring to Align Business with Current Market Conditions - Angiology
Cardium's InnerCool Announces Launch of New Enhanced Website - Angiology
Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results - Angiology
Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips - Biologics
SAFC Pharma Augments Assay Development Capabilities - Biotechnology Business
bioMerieux Introduces Surveillance Tool to Fight Healthcare-Associated Infections - More from this issue of Medical Device Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
